Fundraising Fox
Nurocor
Austin, US · Delaware corporation · 1 known investors
Find your way into Nurocor
Sign up to see every warm intro you have to Nurocor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nurocor team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nurocor offers an AI-native clinical platform that converts clinical trial protocols from static documents into structured, machine-readable digital assets, automating study design, standards governance (CDISC, ICH M11, USDM), specimen management, and document authoring. It serves pharmaceutical companies aiming to reduce cost and time in clinical development.
Founders & leadership
GM
Gregg MartinExecutive
AL
Alex LazarFounder, Board Member, President, and CEOExecutive Officer and Director of Nurocor, which offers an AI-native clinical platform that automates clinical trial protocol structuring, standards governance, and study design for pharmaceutical companies.
GM
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 6 of 7 rounds · 2022–2025
▶$460KraisedMay 2025 · 8 investors · Other TechnologyRule 506(b)
▶$460KraisedMay 2025 · 8 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Gregg MartinExecutive Officer, Director
- Paul GiggExecutive Officer, Director
- Alex LazarExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $460K
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedApr 2025 · 1 investors · Other TechnologyRule 506(b)
▶$500KraisedApr 2025 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul GiggExecutive Officer, Director
- Gregg MartinExecutive Officer, Director
- Alex LazarExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$125KraisedFeb 2025 · 1 investors · Other TechnologyRule 506(b)
▶$125KraisedFeb 2025 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Alex LazarExecutive Officer, Director
- Paul GiggExecutive Officer, Director
- Gregg MartinExecutive Officer, Director
- Offering amount
- $125K
- Amount sold
- $125K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedFeb 2025 · 1 investors · Other TechnologyRule 506(b)
▶$250KraisedFeb 2025 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul GiggExecutive Officer, Director
- Alex LazarExecutive Officer, Director
- Greg MartinExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedOct 2024 · 27 investors · Other TechnologyRule 506(b)
▶$5MraisedOct 2024 · 27 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Gregg MartinExecutive Officer, Director
- Alex LazarExecutive Officer, Director
- Paul GiggExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $5M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$350KraisedOct 2024 · 1 investors · Other TechnologyRule 506(b)
▶$350KraisedOct 2024 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul GiggExecutive Officer, Director
- Gregg MartinExecutive Officer, Director
- Alex LazarExecutive Officer, Director
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2022 · Other TechnologyRule 506(b)
▶Undisclosed amountofferedJun 2022 · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul GiggExecutive Officer
- Alex LazarExecutive Officer
- Greg MartinExecutive Officer
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
NovoCureNovocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
OracleOracle sells enterprise database software, applications and cloud infrastructure, and has grown through large acquisitions including PeopleSoft, Siebel and Sun Microsystems.
Companies working in the same space as Nurocor.
In the news
Frequently asked questions
- What does Nurocor do?
- Nurocor offers an AI-native clinical platform that converts clinical trial protocols from static documents into structured, machine-readable digital assets, automating study design, standards governance (CDISC, ICH M11, USDM), specimen management, and document authoring. It serves pharmaceutical companies aiming to reduce cost and time in clinical development.
- Who are Nurocor's investors?
- Nurocor's investors include Recurring Capital Partners.
- How much funding has Nurocor raised?
- Nurocor has disclosed $6.6M raised across 6 of its 7 known rounds.
- Where is Nurocor headquartered?
- Nurocor is headquartered in Austin, US.